Table 3.
Drug use and PKDL presentation in VL-treated cases, Bihar, India
| Anti-leishmanial drug | No. (%) patients | Median time lapse after treatment (months) | Range (months) |
|---|---|---|---|
| Sodium antimony gluconate | 62 (72.9) | 23 | 1–192 |
| Amphotericin B | 13 (15.3) | 29 | 8–106 |
| AmBisome | 2 (2.4) | 9 | 5–13 |
| Miltefosine | 4 (4.7) | 31 | 29–42 |
| Paramomycin | 4 (4.7) | 25 | 19–37 |
PDKL = post–kala-azar dermal leishmaniasis; VL = visceral leishmaniasis.